Cell Therapy News/Articles, page-4160

Headline:
Gilead Sciences published new data Friday on its antiviral drug remdesivir that shows it reduced the risk of death for severely sick coronavirus patients by 62% compared with standard care alone.

Actual data:

• Gilead said it analyzed data from 312 patients enrolled in its phase three trial and compared it with that of 818 patients in “a real-world retrospective cohort” with similar characteristics and disease severity who received standard care alone during the same time period as the phase three trial.
• “While not as vigorous as a randomized controlled trial, this analysis importantly draws from a realworld setting and serves as an important adjunct to clinical trial data, adding to our collective understanding of this virus and reflecting the extraordinary pace of the ongoing pandemic,” Dr. Susan Olender of Columbia University Irving Medical Center said in a statement.
• The findings show that 7.6% of patients treated with remdesivir died compared with 12.5% of patients in the analysis who did not receive remdesivir treatment. The analysis also found that 74.4% of patients who received treatment with remdesivir recovered by day 14 compared with 59% of patients who received standard care alone.